Interested in learning more about our precision prevention programs or partnerships?
Please contact us at email@example.com
Screening for colorectal cancer (CRC) can improve disease prognosis by identifying early-stage CRC that is easier to treat and has a lower mortality rate than CRC detected after symptoms develop. Screening can also prevent CRC by detecting and removing premalignant polyps before they progress to CRC.
Studies indicate that coloscopy, sigmoidoscopy, and both guaiac-based fecal occult blood testing and fecal immunochemical tests are each associated with a decreased risk of CRC mortality. Abnormal results of initial noninvasive screening tests other than coloscopy necessitate a coloscopy to evaluate the abnormality. Most professional society guidelines and expert groups (US Preventive Services Task Force) recommend screening to be initiated at age 50 and continued until at least age 75 for average-risk adults.
Colorectal cancer has a significant heritable component similar to several other tumor types. Considering the heritability and genetic risks help planning more effective prevention and screening designs. Genetic CRC risk modifying genetic variants can be combined into polygenic risk scores which can be used for designing personalized screening based on the use of fecal occult blood testing and coloscopy.
Antegenes has developed a polygenic risk score based genetic test – AnteCRC. The aim of AnteCRC is to provide a basis for reducing the risk of premature mortality.
AnteCRC is an important part of our colorectal cancer precision prevention program. The program builds on AnteCRC to help identify pre-cancerous conditions as well as early-stage tumors without symptoms by providing individualized schedules and designs of immunochemical testing and coloscopy based on polygenic risks.
The program includes the use of AnteCRC and is suitable for women and men between ages 40 – 75.